@article{7e4fce208991470aa3dc5dce3ff5ea99,
title = "Treat to target with ustekinumab for Crohn's disease",
author = "Ungaro, {Ryan C.} and Colombel, {Jean Frederic}",
note = "Funding Information: RCU has served as an advisory board member or consultant for AbbVie, Bristol Myers Squibb, Janssen, Pfizer, and Takeda; and has received research support from AbbVie, Boehringer Ingelheim, Eli Lily, and Pfizer. J-FC reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, GlaxoSmithKline, Geneva, Iterative Scopes, Janssen Pharmaceuticals, Kaleido Biosciences, Landos, Otsuka, Pfizer, Prometheus, Sanofi, Takeda, and TiGenix; and holds stock options in Intestinal Biotech Development. RCU is supported by an NIH K23 Career Development Award (K23KD111995-01A1).",
year = "2022",
month = apr,
doi = "10.1016/S2468-1253(22)00019-X",
language = "English",
volume = "7",
pages = "276--277",
journal = "The Lancet Gastroenterology and Hepatology",
issn = "2468-1253",
publisher = "Elsevier Ltd.",
number = "4",
}